161 related articles for article (PubMed ID: 1433372)
1. Can thymidine kinase levels in breast tumors predict disease recurrence?
O'Neill KL; Hoper M; Odling-Smee GW
J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
[TBL] [Abstract][Full Text] [Related]
2. Breast tumour thymidine kinase levels and disease recurrence.
O'Neill KL; McKelvey VJ; Hoper M; Monteverde H; Odling-Smee GW; Logan H; Abram WP; McKenna PG
Med Lab Sci; 1992 Dec; 49(4):244-7. PubMed ID: 1339926
[TBL] [Abstract][Full Text] [Related]
3. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.
McKenna PG; O'Neill KL; Abram WP; Hannigan BM
Br J Cancer; 1988 Jun; 57(6):619-22. PubMed ID: 3408646
[TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase 1 activity in breast cancer.
Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
6. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer.
Romain S; Christensen IJ; Chinot O; Balslev I; Rose C; Martin PM; Thorpe SM
Int J Cancer; 1995 Mar; 61(1):7-12. PubMed ID: 7705935
[TBL] [Abstract][Full Text] [Related]
8. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
[TBL] [Abstract][Full Text] [Related]
9. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
10. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
13. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
[TBL] [Abstract][Full Text] [Related]
15. Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer.
Zhang HJ; Kennedy BJ; Kiang DT
Breast Cancer Res Treat; 1984; 4(3):221-5. PubMed ID: 6487823
[TBL] [Abstract][Full Text] [Related]
16. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.
Bolayirli M; Papila C; Korkmaz GG; Papila B; Aydoğan F; Karataş A; Uzun H
J Clin Lab Anal; 2013 May; 27(3):220-6. PubMed ID: 23686779
[TBL] [Abstract][Full Text] [Related]
17. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
18. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
19. AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays.
Kumar JK; Holmgren S; Levedahl KH; Höglund M; Venge P; Eriksson S
Biotechniques; 2020 Jun; 68(6):334-341. PubMed ID: 32336110
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte thymidine kinase and treatment response in acute lymphocytic leukemia.
Russo SA; Harris MB; Greengard O
Leuk Res; 1987; 11(2):149-54. PubMed ID: 3469483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
